Illumina (ILMN) Stock Price, News & Analysis

Company Overview

Illumina, Inc. (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays. Illumina also provides software and informatics solutions to support data analysis and workflow management, along with services and support for adoption of genomics in research and clinical settings. Its offerings are designed to address whole-genome, exome, transcriptome and targeted sequencing needs across discovery and diagnostic workflows.

Illumina operates globally, selling products and services across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. Since its founding, the company has played a central role in lowering the cost and increasing the throughput of DNA sequencing, enabling broader use of genomic tools in research and medicine. Illumina’s strategy emphasizes technological innovation, partnerships and an executive leadership team and board that guide product development, commercial operations and regulatory and market access activities worldwide.

Key Stats

• Today's Range: $137.10 to $142.40
• 50-Day Range: $115.56 to $142.58
• 52-Week Range: $75.24 to $155.53
• Volume: 734,783 shs
• Average Volume: 1.87 million shs
• Market Capitalization: $20.88 billion
• P/E Ratio: 25.08
• Dividend Yield: N/A
• Price Target: $131.06
• Consensus Rating: Hold

Illumina Stock Analysis - MarketRank™

Illumina scored higher than 62% of companies evaluated by MarketBeat, and ranked 301st out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Illumina has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 6 buy ratings, 10 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Illumina is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Illumina has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.08%

Earnings Growth

Earnings for Illumina are expected to grow by 13.08% in the coming year, from $5.20 to $5.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Illumina is 25.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.44.

Price to Earnings Ratio vs. Sector

The P/E ratio of Illumina is 25.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.56.

Price to Earnings Growth Ratio

Illumina has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Illumina has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.85% of the float of Illumina has been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 5.22.

Change versus previous month

Short interest in Illumina has recently increased by 3.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Illumina does not currently pay a dividend.

Dividend Growth

Illumina does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.88

News Sentiment

Illumina has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Illumina this week, compared to 10 articles on an average week.

Search Interest

20 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

9 people have added Illumina to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Illumina insiders have sold 1,068.61% more of their company's stock than they have bought. Specifically, they have bought $23,562.00 in company stock and sold $275,347.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Illumina is held by insiders.

Percentage Held by Institutions

89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ILMN Stock Analysis - Frequently Asked Questions

How have ILMN shares performed this year?

Illumina's stock was trading at $131.16 at the beginning of the year. Since then, ILMN shares have increased by 4.7% and is now trading at $137.3190.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, April, 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.10. Illumina's quarterly revenue was up 4.8% compared to the same quarter last year.
Read the conference call transcript.

Does Illumina have any subsidiaries?

Illumina subsidiaries include these companies: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others.

Who are Illumina's major shareholders?

Top institutional investors of Illumina include Bank of New York Mellon Corp (0.99%), Sumitomo Mitsui Trust Group Inc. (0.68%), Vaughan Nelson Investment Management L.P. (0.57%) and Swiss National Bank (0.30%). Insiders that own company stock include Susan H Tousi, Scott M Davies, Patricia Leckman, Jacob Thaysen, Scott Gottlieb and Aimee L Hoyt.
View institutional ownership trends.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/07/2026
• AGM 2026: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ILMN
• CIK: 1110803
• Web: www.illumina.com
• Phone: (858) 202-4500
• Fax: 858-202-4766
• Employees: 8,650
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Illumina: $131.06
• High Price Target: $170.00
• Low Price Target: $94.00
• Potential Upside/Downside: -5.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.22
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.50
• Trailing P/E Ratio: 25.08
• Forward P/E Ratio: 26.54
• P/E Growth: 2.3
• Net Income: $850 million
• Net Margins: 19.42%
• Pretax Margin: 24.15%
• Return on Equity: 31.01%
• Return on Assets: 12.22%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 1.75
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $4.34 billion
• Price / Sales: 4.81
• Cash Flow: $6.66 per share
• Price / Cash Flow: 20.71
• Book Value: $17.69 per share
• Price / Book: 7.80

Miscellaneous

• Outstanding Shares: 151,300,000
• Free Float: 147,502,000
• Market Cap: $20.88 billion
• Optionable: Optionable
• Beta: 1.42